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Abstract
Background: About half of people with glaucoma do not adhere to their recommended medications. Interventions
for other chronic conditions have successfully utilized reminder systems and motivational interviewing (MI)-based
counseling. This study was designed to pilot a personalized intervention that leverages these strategies to assess their
impact on medication adherence in glaucoma patients.
Methods: Glaucoma patients taking ≥ 1 medication will be pre-screened by telephone survey for adherence to their
medication(s). Those who self-report poor adherence will be enrolled in a 3-month monitoring period to measure
medication adherence using electronic medication monitors. Participants who are non-adherent (take </=80% of their
medication doses) over the 3-month run in phase will be eligible for the study. We plan to enroll 57 participants who
are non-adherent to their medications. Participants’ adherence will then be continuously measured with electronic
medication monitors, by self-report, and via pharmacy refill data over 2 years, during which two successively more
resource-intensive components of an intervention aimed to improve medication adherence will be administered. The
first component is a 3-month period of reminders (audio and/or visual) and text message or automated phone call if a
dose of medication is not taken within a pre-specified time frame. The second component is a 6-month MI-based
counseling program with a trained glaucoma counselor. This component uses the eyeGuide, a computer-based
personalized behavior change program that enables para-professional staff to provide personalized education and
counseling for glaucoma. The primary outcome is change in medication adherence. The secondary outcomes include
changes in clinical outcomes (intraocular pressure, IOP, and IOP fluctuation) and psychosocial mediators of adherence (e.g.,
competence, energy for change and satisfaction). Participants will undergo semi-structured interviews at 12 months to give
feedback about the counseling program in order to improve it.
Discussion: This pilot study will provide insight into ways to deliver more personalized health care to non-adherent
glaucoma patients in order to better support them in managing their chronic disease.
Trial registration: Retrospectively registered with ClinicalTrials.gov (NCT03159247).
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Background
Despite evidence from randomized clinical trials that
medication reduces vision loss from glaucoma [1, 2], it
remains the second leading cause of blindness in the
United States (US) [3]. One major contributor to this is
that about one-half of glaucoma patients are essentially
“untreated” because they do not adhere to their medica-
tions [4, 5]. Poor adherence and poor clinical outcomes
disproportionately affect the most vulnerable members
of US society, older people, and minorities [6, 7]. As life
expectancy in the US continues to increase, the preva-
lence of glaucoma will also increase. As there is already
a projected shortage of ophthalmologists in the work-
force [8], we will need to re-think the current paradigm
of how a single physician is responsible for medical deci-
sion making, surgical intervention, counseling and edu-
cating patients, and coordinating care in a complex
medical system. Team-based care is becoming essential
where a larger team of medical staff help support
patients’ chronic disease self-management. There is a
compelling need to develop and test technology-based
solutions to improving the quality of care a medical
team can provide to improve medication adherence and
the outcomes of care for patients with glaucoma.
Poor adherence to effective medications is a critical
barrier to achieving better outcomes in glaucoma pa-
tients. The World Health Organization stated that “in-
creasing the effectiveness of adherence interventions
may have a far greater impact on the health of the popu-
lation than any improvement in specific medical treat-
ments [9].” Once diagnosed with glaucoma, at least half
of patients do not adhere to their glaucoma medication
regimen [4, 5, 10], return for follow-up [6], or persist
with their medications over the longer term [11]. Pa-
tients who are not adherent have more severe visual field
loss [12–14], which leads to steep declines in
health-related quality of life [15–18] and increased risk
of falls and motor vehicle accidents [19].
Adherence to glaucoma medications is rarely addressed
during the clinical encounter [20, 21] because education
and counseling programs are not part of standard glau-
coma care. Qualitative research has demonstrated that pa-
tients often have a poor understanding of glaucoma and
its treatment [22–25]. In addition to knowledge gaps, pa-
tients have numerous concrete and psychological barriers
to managing their glaucoma such as skepticism that glau-
coma will cause vision loss in the future when it is asymp-
tomatic, issues with side effects and medication cost,
problems remembering to take medication, and difficulties
properly instilling the medication [26–28]. Eye drop instil-
lation is rarely taught during the clinic visit, and many pa-
tients cannot properly instill their drops [29, 13]. For
example, among glaucoma patients with visual impair-
ment, one-third of patients who thought they could cor-
rectly instill their eye drops did not get their eye drop into
their eye when they were video-recorded [29].
Uniform, scripted approaches to improve adherence have
been shown to be ineffective [30, 31]. However, complex,
individualized counseling interventions, especially those
based in motivational interviewing (MI), have been shown
to improve adherence and health outcomes in many
chronic diseases [30, 31]. MI is a style of counseling that
engages patients by discussing priorities and obstacles to fa-
cilitate intrinsic motivation to change health behavior [32].
MI is a counseling style consistent with the theoretical
framework of self-determination theory [33], which postu-
lates that an individual must develop personally compelling
reasons to motivate a change in behavior. Self-motivation
depends on meeting three basic psychological needs: re-
latedness, autonomy, and competence. A collaborative dis-
cussion based in MI techniques allows these needs be met
and creates “energy for change.” (Fig. 1). Relatedness is pro-
moted by expressing empathy during counseling. Auton-
omy is supported when the counselor helps the person
overcome ambivalence and identify his own values and
goals for managing disease. MI supports competence and
Fig. 1 Self-determination theory based theoretical model
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self-efficacy by equipping the person with the knowledge
and skills to work through barriers and implement routines
to maintain the behavior change (create an “action plan”).
MI and SDT will serve as the health communications
framework for the tailored strategies for our interventions
in the non-adherent glaucoma patient population. Few
complex interventions based on these successful principles
have been rigorously tested and none have been imple-
mented into glaucoma care.
The eyeGuide is a web-based, personally tailored, behav-
ior change program based on MI principles and self-deter-
mination theory, developed from a systematic review of
the glaucoma adherence literature [34], data from focus
groups [35] and surveys [26], and iterative beta-testing
with glaucoma patients [36] (Fig. 2). The eyeGuide was
developed with user centered design; we tested the eye-
Guide with patients and providers and when more than
one person suggested something should be changed, we
changed it. We continued this process until we no longer
received substantive comments from patients and pro-
viders, which occurred after testing with 40 patients and 8
providers through three major design changes. The eye-
Guide has two components woven together into a single
web-based tool: an electronic health (eHealth) component
and a semi-structured, tailored interview guide to facilitate
an MI-based conversation. The eHealth component pro-
vides individually tailored disease and treatment informa-
tion, and information on how other patients overcame
similar barriers to optimize their disease self-management.
Such technology-based eHealth innovations have great
potential to extend the reach of physicians by enabling
team-based care.
In this pre-post design pilot study, we will test the ini-
tial impact of two sequentially more resource-intensive
components of a personalized eHealth intervention on
medication adherence among non-adherent glaucoma pa-
tients: (1) real-time automated adherence reminders and
(2) the eyeGuide MI-based counseling program. We will
also explore the preliminary effects of these interventions
on secondary outcomes including psychosocial mediators
of adherence (e.g., competence, energy for change, satisfac-
tion) and clinical parameters (intraocular pressure (IOP)
and IOP fluctuation).
Methods/design
In order to test the preliminary impact of the personalized
eHealth intervention among non-adherent glaucoma
patients, we will electronically monitor medication adher-
ence longitudinally over 2 years. The two main compo-
nents to be evaluated are (1) real-time automated
adherence reminders using commercially available Adher-
eTech electronic medication monitors (AdhereTech, New
York, USA) and (2) in-person tailored counseling with a
medical assistant trained in MI (the eyeGuide program).
Adherence will be monitored for all patients for a total of
2 years. Adherence will first be monitored for a 3-month
period prior to the intervention to obtain baseline adher-
ence and mitigate issues with regression to the mean and
the Hawthorne effect [37]. Adherence will then be mea-
sured over a nine-month period of time during which the
two interventions will be sequentially administered. Fi-
nally, adherence will be measured for 1 year after the con-
clusion of intervention to assess how well change in
adherence is maintained over time.
Fig. 2 eyeGuide tool screenshots
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Ethics, consent, and permissions
Approval for the study was obtained from the University
of Michigan Institutional Review Board (HUM00112614).
Eligible participants will be assessed for willingness to par-
ticipate in the study. Informed consent will be obtained at
the first study visit for study participation alongside per-
mission to access health information from the medical
record and pharmacy refill data from participants’
pharmacies.
Participants
Participants who have been seen at the University of
Michigan Kellogg Eye Center, have a diagnosis of glau-
coma (including glaucoma suspect and ocular hyperten-
sion), are aged ≥ 40, take ≥ 1 glaucoma medication, and
speak English will be eligible to participate in the study.
Eligible glaucoma patients will be sent a letter explaining
the study along with an option to opt out of recruitment.
Those who do not opt out will be called and their adher-
ence status will be assessed by two survey methods of
self-report to increase the probability of recruiting truly
non-adherent patients (see Additional file 1 for measures
to assess self-reported medication adherence). We will
exclude patients who do not administer their own eye
drops or who have a diagnosis of cognitive impairment
or severe mental illness.
Baseline eligibility assessment
Adherence will be measured electronically for 3 months
prior to the first intervention to determine study eligibil-
ity and obtain a baseline, pre-intervention measure of
medication adherence. The participant’s medication(s)
and dosing schedule is determined by first reviewing the
patient’s medical record and then confirming the medi-
cations with the patient. The study coordinator will rec-
ord these data into the AdhereTech system. Participants
will place their glaucoma medications inside Adhere-
Tech electronic medication monitors that look like pill
bottles. Patients will have different monitors for each of
their glaucoma medications. Each time a bottle is
opened, and the time and date are recorded. These re-
cords will be collected in real time and transmitted
through the cellular data network so that adherence to
medications can be calculated at any time interval
(weekly, biweekly, monthly, etc.). The study coordinator
will record each participant’s adherence data in the med-
ical record during their study visits.
An adherent event is defined as taking medication
within a specified time window of a dose on the previous
day. For a once daily medication, an adherent event is
defined as taking the medication within 24 ± 4 h of the
previous day’s dose. For a twice daily medication, an ad-
herent event is defined as taking the first medication
dose within 24 ± 2 h of the previous day’s first dose and
taking the second medication dose within 24 ± 2 h of the
previous day’s second dose. For a three times daily medi-
cation, an adherent event is defined as taking the medi-
cation dose (first, second, or third) within 24 ± 1.3 h of
the previous day’s corresponding medication dose (first,
second, or third). For a four-time daily medication, an
adherent event is defined as taking the medication dose
(first, second, third, or fourth) within 24 ± 1 h of the pre-
vious day’s corresponding medication dose. The bio-
logical efficacy of medications dosed multiple times daily
declines when not taken on time [38–40]. However,
when calculating adherence for medications dosed more
than once a day, we compare the current day’s doses to
the previous day’s corresponding doses rather than sim-
ply the previous dose (second versus first, or third versus
second) as lifestyle and sleeping patterns can result in
medication times that are not equally spaced. This
method of calculating adherence also allows for large
shifts (time zone changes for work or vacation) or grad-
ual changes in times when medications are taken with-
out overly penalizing the patient, which can happen
when calculating adherence relative to a median time.
Additionally, this method of measuring adherence en-
sures that adherence credit is not given for instances
where bottles are opened numerous times just prior to a
clinic visit [119]. For participants on more than one
medication, adherence will first be measured at the
medication level and then aggregated to the person level
by dividing the total number of doses of all medica-
tion(s) taken on time by the total number of doses of all
medication(s) prescribed. Baseline adherence will be cal-
culated monthly during the 3-month monitoring period.
The median monthly adherence will be designated as
the baseline adherence score; choosing the median will
help to mitigate the effects of regression to the mean.
We will exclude patients from participating in the study
whose median baseline adherence score is > 80% on all
of their glaucoma medications after a baseline observa-
tion period of 3 months.
Timeline
The glaucoma counselor will meet with the participants
in-person for seven study visits (Fig. 3). Intraocular pressure
(IOP) will be measured at each study visit. The first study
visit will include obtaining written informed consent, taking
a 60-min survey and being instructed on how to use the
AdhereTech electronic medication monitors. Three months
later, during the second study visit, participants will be noti-
fied of their eligibility to continue in the study.
Eligible patients will participate in five more study visits.
At the third study visit, 6 months from enrollment, partic-
ipants will have their first 60-min eyeGuide counseling
session with the glaucoma counselor and will take a
30-min survey. Their eye drop instillation will also be
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video-recorded. At the fourth study visit, 8 months from
enrollment, participants will have their second 30-min
eyeGuide counseling session and will take a 10-min sur-
vey. At their fifth study visit, 10 months from enrollment,
they will have their final 30 min eyeGuide counseling ses-
sion and have their eye drop instillation technique
video-recorded. The intervention will end at the sixth
study visit, 12 months from enrollment, where partici-
pants will come in to take a 45-min survey and undergo a
30-min semi-structured interview to obtain qualitative
feedback about the eyeGuide program. Between the
in-person eyeGuide counseling sessions, the glaucoma
counselor will check-in with participants by telephone to
update them on their adherence and discuss any issues
they are having. These check-ins will take place more fre-
quently at the beginning of the eyeGuide intervention, at
2 week intervals, and less frequently toward the end of the
eyeGuide intervention (at 1 month intervals; Fig. 3). Partic-
ipants will continue using their electronic medication mon-
itors for an additional 12 months after the intervention has
ended. At the seventh and final study visit, 24 months from
enrollment, participants will return their electronic medi-
cation monitors and take a 45-min survey. Participants will
receive a $35 stipend for each of their seven study visits
and $35 for returning their adherence monitors.
Personalized intervention tested in a pre-post design
Component 1
Participants will decide on a daily time when they would
like to receive an automated reminder to take each dose
of all of their glaucoma medications if they have not yet
taken the dose. The reminder will be either an automated
phone call or text message. Participants can also choose to
activate an audio or visual alert [41–43]. AdhereTech will
provide all of the preferred automated alerts. Participants’
adherence will be monitored throughout the 3-month
period of receiving these automated reminders.
Component 2
After 3 months of receiving the automated reminders,
participants will begin the tailored eyeGuide program.
The program is tailored using computer programming
so that the information each participant receives is per-
sonalized to their demographics and circumstances. The
eyeGuide is tailored on the following variables: name,
gender, race/ethnicity, ophthalmologist’s name, ophthal-
mologist’s gender, glaucoma type, past glaucoma surger-
ies or lasers, optic nerve photographs, visual field test
results, use of the internet and/or smartphone, family
support for eye drop instillation, and barriers to optimal
glaucoma medication adherence.
Using the eyeGuide tablet-based tool, the glaucoma
counselor will teach eye drop instillation, provide educa-
tion tailored to a participant’s test results, elicit the bar-
riers the participants face in managing their glaucoma,
share tailored patient testimonials about strategies other
patients used to overcome similar barriers, and brain-
storm solutions together during the three in-person
counseling sessions. The counselor will collaborate with
participants to form an “action plan”—a short-term plan
Fig. 3 Pilot study timeline
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of steps to use to address identified barriers including
how to integrate glaucoma medications into daily life
(Fig. 2) [44–46]. The counselor will call participants
once every 2 weeks between the first two eyeGuide study
visits and then once monthly to provide feedback on
their adherence level, check-in on their action plan, and
help the participant identify new action steps. In-person
counseling sessions will take place in a small Wi-Fi-en-
abled conference room at the Kellogg Eye Center located
nearby an examination room where IOP measurement is
taken.
Participants will receive 170 min of counseling (one
60-min counseling session, two 30-min counseling ses-
sions, and five 10-min telephone calls), within the range
of counseling time (106 ± 92.4 min) that achieved signifi-
cant results in a meta-analysis of motivational interview-
ing [46]. The glaucoma counselor will also update the
participant’s ophthalmologist on their adherence and ac-
tion plan. Participants can call the counselor if questions
arise during the intervention.
Glaucoma-specific brief MI training program development
An ophthalmic technician will be trained as a glaucoma
counselor through a glaucoma-specific brief MI training
program that the study team has developed. The glau-
coma-specific brief MI training program was developed
by two behavioral psychologists and a psychotherapist
trained through the Motivational Interviewing Network
of Trainers [47]. The training program includes 16 h of
didactic group training and 2 h of individualized coach-
ing sessions. During the first training session, the pro-
spective counselor learns about the following
components of brief-MI-based conversation: reflective
listening, asking open-ended questions, using affirma-
tions, using elicit-provide-elicit technique to teach eye
drop instillation, and summarizing [32]. The
elicit-provide-elicit technique includes assessing the pa-
tient’s knowledge prior to giving information, asking per-
mission to give new information, and then following up
by eliciting patients’ response to the new information to
evaluate their understanding.
The second training session focuses on learning how
to problem-solve issues that may arise in patient en-
counters and learning how to make complex reflec-
tions. A reflection is a statement that paraphrases what
the patient said to demonstrate active listening; a com-
plex reflection is a statement that paraphrases and adds
significant meaning. Prospective counselors also learn
how to identify and promote change talk and develop
an action plan to improve medication adherence. A
video collection of glaucoma patients explaining their
reasons for discontinuing their glaucoma medications is
used for role playing during the training. Each session
includes both didactic presentations and role playing
(Table 1).
To ensure fidelity to MI training, the glaucoma counselor
will practice delivering the intervention with at least five
volunteer patients. S/he will be audio-recorded, and feed-
back will be provided prior to beginning the study. Compe-
tence in MI will be met before study visits are conducted.
All study visit counseling sessions will be audio- recorded,
and a random sample of sessions will be graded with a vali-
dated coding system tailored to the study, the One-Pass
coding system [48] (Additional file 2, Glaucoma-specific
one-pass). In addition to the initial training, the counselor
will receive feedback on the graded sessions during booster
training sessions over the course of the intervention [49].
The protocol for the eyeGuide intervention meets the Tem-




The primary outcome is change in medication adherence
(continuous variable for percentage of medication doses
taken on time) measured by electronic medication moni-
tors after each intervention. We will also measure adher-
ence by three additional techniques in order to reflect
different aspects of adherence behavior [51] and com-
pare the techniques to one another: (a) video-recorded
drop instillation, (b) self-reported adherence [52–55],
and (c) pharmacy refill data. To assess how well patients
can properly instill their eye drops, we will video-record
patients instilling their eye drops during their third and
fifth study visits, before and at the end of the eyeGuide
intervention, respectively. Two masked assessors will
review the videos and assess each participant for the
following three techniques: (1) does the participant
dispense a single drop, (2) does the drop get into the
eye, and (3) does the participant touch the dropper tip
to the ocular adnexa or extraocular structures. Self-re-
ported adherence will be assessed with the Morisky
questionnaire [56] (eight items, Cronbach α = 0.83), the
Adherence to Refills and Medications Scale [57] (ARMS,
12 items, α = 0.81), and three additional questions about
adherence from the glaucoma literature [55, 51]. These
adherence questionnaires will be given at the baseline,
3-, 6-, 12-, and 24-month study visits.
Pharmacy refill data will be obtained by calling each par-
ticipant’s pharmacy every 3 months to identify whether
each prescribed medication has been filled. The medica-
tion possession ratio (MPR) is the proportion of days dur-
ing a fixed time period where the patient had an adequate
supply of medication to use at the prescribed frequency.
MPR will be calculated at the patient level after combining
refill data from all medications during a defined time
period, as follows:
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In this study, MPR will be calculated during fixed,
quarterly time intervals of 91–92 days from enroll-
ment, as well as cumulatively over each intervention
period. The participants’ pharmacies will be called
after a quarter has been completed to obtain refill
information (date of fill, medication dispensed, day’s
supply, number of mLs dispensed). In the event of
overlapping refills, it will be assumed that medications
are taken sequentially, not doubly dosed, to avoid an
MPR greater than 1.
MPR ¼ #days correct amount of medication 1þ…þ #days correct amount of medication 4
#elapsed days medication 1þ…þ #elapsed days medication 4
Table 1 Glaucoma-specific brief motivational interviewing training curriculum
Training session 1 Training session 2
Knowledge review Presentation using “Elicit-Provide-Elicit”: “Motivational
Interviewing Basics”
Review using E-P-E: “Skills learned in session 1”
Skill review: “Quiz open vs. closed questions”
Skills/knowledge development Paired activity: “A Taste of MI” Group activity: “Health and Safety Quiz”
Didactic using E-P-E: “What is reflective listening” Triad activity: “Ambivalence”
Paired activity: “Non verbal listening practice” Didactic using E-P-E: “MI Spirit”
Paired activity: “Hypothesis testing” Didactic using E-P-E: “Simple vs. complex reflections”
Paired activity: “Forming reflections” Individual activity: “Reflective responses to sentence
stems—three levels”
Individual activity: “Forming reflections with sentence
stems”
Paired activity: “Reflection practice”
Group activity: “Forming reflections to glaucoma patient
video examples”
Didactic using E-P-E: “Affirmations”
Didactic using E-P-E: “Open ended questions” Paired activity: “Making affirmations”
Paired activity: “Asking open-ended questions” Didactic using E-P-E: “Making summaries”
Didactic using E-P-E: “Elicit-provide-elicit” Paired activity: “Making summaries”
Paired activity: “Teaching eye drop instillation with elicit-
provide-elicit”
Didactic using E-P-E: “Eliciting change talk”
Didactic using E-P-E: “Summarizing: Paired activity: “Using elicit-provide-elicit to teach eye drop
instillation”
Paired activity: “Making summaries” Didactic using E-P-E: “Importance Ruler”
Paired activity: “Doing a full patient encounter using the
MI skills learned”
Didactic using E-P-E: “Exploring goals and values”
Paired activity” “Exploring goals and values”
Didactic using E-P-E: “Confidence Ruler”
Didactic using E-P-E: “Exploring strengths”
Paired activity: “Rulers and strengths”
Didactic using E-P-E: “Change Talk vs. Sustain Talk”
Didactic using E-P-E: “Action Planning”
Paired activity: “Putting it all together”
Skills Demonstration Role playing: “Reflective listening” Video demonstration: “Making Affirmations”
Role playing: “Patient encounter using MI” Video demonstration: “Making summaries”
Video demonstration: “Elicit-Provide-Elicit for Change Talk”
Video demonstration: “Exploring goals and values”
Role play: “Rolling with resistance”
Skills self-reflection Debrief: “What was learned?” Debrief: “How will you implement this in clinic”
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Secondary outcomes
Secondary patient outcomes include changes in clinical
outcomes, changes in psychosocial mediators of adher-
ence, and intervention impact on patient satisfaction.
Our clinical outcome is IOP and IOP fluctuation [58],
which will be measured during each study visit and col-
lected from clinic visits that participants have during the
study period (expect 7–9 measurements from study
visits and clinic visits). IOP will be checked at each
in-person study visit using Goldmann applanation to-
nometry. Any additional IOP measurements taken dur-
ing clinic visits during participants’ time in the study
will be abstracted from the electronic health record.
The two psychosocial mediators of adherence in our
theoretical model (Fig. 1) include (1) change in perceived
glaucoma skills (perceived competence [59]), glaucoma
knowledge [60], glaucoma medication and eye drop in-
stillation self-efficacy [61], goal setting [62], and propen-
sity to ask questions of their physician [63]) and (2)
change in energy for change (motivational state [64] and
autonomy [65]) after each intervention. We will also as-
sess the intervention’s impact on patient satisfaction
(satisfaction with information about glaucoma [66] and
client satisfaction [67, 68]).
Validated measures will be used to assess these pro-
posed mediators of adherence. Skills will be measured
with five constructs: perceived competence, glaucoma
knowledge, self-efficacy, goal setting, and confidence
asking the physician questions. Perceived competence
[59] (four items, Cronbach α = 0.80) assesses partici-
pants’ perceptions of how able they are to manage their
glaucoma on a seven-point Likert scale. Perceived com-
petence will be measured at the baseline, 6-, 12-, and
24-month study visits. Glaucoma Knowledge will be
assessed with a 10-item true/false test generated by the
National Eye Institute (NEI) [60]. Glaucoma knowledge
will be measured at the 3- and 8-month study visits, be-
fore and after the eyeGuide intervention, respectively,
and at the 24-month study visit. Glaucoma medication
and eye drop instillation self-efficacy [61] (medication
self-efficacy, 10 items, eye drop instillation self-efficacy,
6 items, α = 0.91 for all 16 items) assess participants’
self-confidence in using their eye drop medications as
prescribed and instilling them into their eyes correctly
using a three-point Likert scale. Glaucoma medication
and eye drop instillation self-efficacy will be measured at
the baseline, 6-, 12-, and 24-month study visits. Goal set-
ting (three items, α = 0.80) measures whether or not
health care providers asked participants to set goals to
improve how they take care of their chronic disease on a
five-point Likert scale. The Goal Setting Scale is a
sub-scale of the Patient Assessment of Chronic Illness
[62] measure. We could not use the full sub-scale as the
final two questions ask if the person has been asked to
attend a class to help cope with their chronic condition
or asked to fill out a survey about their chronic condi-
tion, neither of which are standard aspects of current
glaucoma care. Goal setting will be measured at the
baseline study visit, and the 12- and 24-month study
visits. Confidence asking the physician questions will be
measured with three items from the adapted Perceived
Efficacy in Patient-Physician Interactions Scale [63]
(PEPPI, five items, α = 0.83) using a five-point Likert
scale. Confidence asking the physician questions will be
assessed at the baseline visit and the 12-month study
visit.
Energy for change will be measured with two con-
structs using two different scales, the Health Care Cli-
mate Questionnaire [65] (HCCQ; 12 items, α = 0.96) and
the Treatment Self-Regulation Questionnaire [64]
(TSRQ; 19 items, α = 0.81). The HCCQ measures per-
ceived autonomy support from health care providers.
The TSRQ measures whether a participant feels moti-
vated to accomplish a health-related goal because of
their own internal desires, such as “I personally believe
that controlling my glaucoma will improve my health”
or whether they take care of their health problem for
reasons external to themselves, like “I want my doctor to
think I’m a good patient.” Both of these scales have been
validated in patients with diabetes and have been
adapted to glaucoma, a similar chronic disease that re-
quires consistent self-management for optimal disease
control, for this study. Both scales use seven-point Likert
scales. The HCCQ and TSRQ will both be given at the
baseline, 6-, 12-, and 24-month study visits.
Satisfaction will be measured in two ways. Satisfaction
with information about glaucoma will be measured using
the Satisfaction with Information Scale [66] (four items).
These questions were developed to assess how patients
with hyperlipidemia felt about the type of information
they received about their disease. The scale uses a seven
point Likert scale to assess satisfaction with the amount
of information received, the clarity of the information,
how helpful the information was, and how well people
now understood how to take their medications. The Sat-
isfaction with Information scale will be given at the
baseline study visit, and the 12-month study visit, at the
conclusion of the eyeGuide intervention. Satisfaction
with the eyeGuide intervention will also be measured at
the 12-month study visit using the Client Satisfaction
Questionnaire [67, 68] (three-item subscale, α = 0.91).
We will explore the effect of possible moderators and
mediators of glaucoma medication adherence, such as total
number of minutes of counseling, socio-demographic
characteristics, visual function [69], health literacy [70, 71],
severity of glaucoma, glaucoma symptoms [72], number of
prescribed classes of glaucoma medications, medical co-
morbidities, perceived stress [73], consideration of future
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consequences [74], barriers to glaucoma medication
adherence [75], social support [76], depression [77, 78],
glaucoma-related distress [79], hopefulness, confidence and
motivation to manage glaucoma [32], and perceived benefit
to glaucoma treatment [80]. These constructs will be
measured using validated instruments or particular items
from validated instruments to assess specific variables
(Table 2). We will also explore the acceptability of and
satisfaction with each level of the intervention through
semi-structured interviews with participants. All partic-
ipants will be interviewed with a semi-structured inter-
view guide (Additional file 3). The number of minutes
of counseling recorded alongside amount of booster
training given will be used as an estimate of potential
labor force costs to implementing the counseling pro-
gram in the clinical setting.
Study specific adverse event reporting
Any physical, social, economic, or psychological harm
attributable to participation in this research study, if
serious, will be reported to the IRB within 7 days and
any non-serious adverse events will be reported with
scheduled continuing review. Examples of possible ad-
verse events include an injury occurring during a
study visit, depression identified during a study visit,
breach of confidentiality, or auto accident on the way
to or from a study visit. Any unrelated deaths while
in the study will be reported to the IRB with sched-
uled continuing review.
Any clinical depression identified during the study will
be handled according to our depression screening
protocol (Additional file 4). Participants who have issues
with medication adherence may have problems because
of underlying psychological distress. Therefore, we will
use the patient health questionnaire (PHQ-9), a validated
measure used clinically to assess for depression [77],
during the 3-, 10-, and 12-month study visits so that all
participants are screened for depression annually and if
a participant is identified as having depressive symptoms
they will be referred to appropriate care (see protocol,
Additional file 4).
Any increases in IOP will be managed by the study
principal investigator (PANC) and study team but are
not considered reportable events to the IRB. When the
participant’s IOP is checked, if it is above the goal pres-
sure that has been set for them by their physician, the
study team will contact their ophthalmologist through
the electronic medical record and via email to let them
know and determine an appropriate follow-up with their
ophthalmologist. If the participant’s IOP is > 21 mmHg,
the PI will be paged and the participant will be seen im-
mediately in the glaucoma clinic by a physician for
further management if medically indicated.
Data and safety monitoring plan
As the study has been deemed to have minimal risk by
the Institutional Review Board (University of Michigan,
Ann Arbor, MI), the Institutional Review Board has rec-
ommended that members of the study team will review
study recruitment, adverse events, and compliance with
the protocol every 6 months.
Table 2 Scales for potential moderators and mediators of glaucoma medication adherence for exploratory analysis
Moderators Mediators Time pointa Original source
Visual function 1 National Eye Institute Visual Function Questionnaire
(Mangione 2011)
Functional health literacy 1 Functional Health Literacy (Chew 2004)
Health literacy 2 Rapid Estimation of Adult Literacy in Medicine
(Arozullah 2007)
Glaucoma symptoms 1 Glaucoma Symptom Scale (Lee 1998)
Perceived Stress 1 Perceived Stress Scale (Cohen 1983)
Consideration of future
consequences
1 Consideration of Future Consequences Scale
(Strathman 1984)
Glaucoma-related distress 1, 3, 5, 6 Diabetes Distress Scale (Polonsky 2005)
Barriers to glaucoma medication adherence 1, 3, 5, 6 Glaucoma Treatment Compliance Assessment Tool
(Barker 2015)
Social support 1, 5, 6 Diabetes Specific Social Support Needs (Rosland 2008)
Depression 2, 5, 6 Patient Health Questionnaire-9 (Kroenke 2001)
Hopefulness, confidence and motivation
to manage glaucoma
1, 3, 5, 6 Hopefullness, Confidence and Motivation Rulers
(Miller and Rollnick 2012)
Perceived benefit to Glaucoma Treatment 1, 5, 6 Perceived Benefits of Treatment (Chao 2005)
aTime Point 1 = baseline (0 months), 2 = intervention 1 (alarms, 3 months), 3 = intervention 2 (eyeGuide, 6 months), 4 = eyeGuide follow-up visit (8 months), 5 =
intervention end (12 months), 6 = end of adherence monitoring (24 months, end of study)
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Statistical design
Data analysis
The primary outcome, adherence, captured by the elec-
tronic monitors, will be a continuous measure from 0 to
100 representing the percent of glaucoma medication
doses taken on time over a specific time period. Baseline
adherence for the 3-month interval before any interven-
tion will be investigated for the Hawthorne effect. Be-
cause simply monitoring a patient can cause them to
temporarily change their behavior, even in the absence
of actual intervention [81], we will plot adherence over
time for each patient during the first 3 months of mon-
itoring. Previous electronic medication monitoring for
glaucoma medications demonstrated that the Haw-
thorne effect wore off after approximately 40 days of
monitoring, which is why we chose to monitor partici-
pants for 90 days [82]. We will investigate plots for pat-
terns of better adherence during the initial weeks of
monitoring and worse adherence during the later weeks
of baseline monitoring. Additionally, we will compare
adherence in earlier vs. later weeks using paired t tests.
If a significant Hawthorne effect is found, we will use
the third month of monitoring data as a baseline adher-
ence score. Although using the worst month of adher-
ence as a baseline score could expose us to regression
to the mean, we would expect outliers in adherence to
be random throughout the 3-month period and not ne-
cessarily bias the results in only the last month of mon-
itoring. Adherence at baseline and after the
intervention will be compared with paired t tests for all
pair-wise comparisons. Adherence 1 year after the end
of all interventions will be evaluated for stability. This
will be investigated with plots, and analyzed with paired
tests and linear mixed regression models (LMM).
LMMs will be used to investigate predictors of adher-
ence. Variables investigated will include participant
characteristics and demographics, clinical measures of
disease severity, and counseling and health literacy
measures. Repeated measures logistic regression with
generalized estimating equations (GEE) will also be
used to investigate predictors of adherence >/=80%.
The repeated measures analyses (LMM and GEE) will
use adherence data gathered over all time points and
account for the correlation within an individual over
time. Moderators of glaucoma medication adherence
will be investigated in the LMMs by interactions with
time, to test the hypothesis that moderators will have
different slopes of medication adherence over time [83].
Mediators of glaucoma medication adherence will be
investigated with a series of LMMs [83]. First, the effect
of the intervention on glaucoma medication adherence
will be tested. Because all participants receive the inter-
vention, this will be a test of slope of medication adher-
ence over time (Ymedication adherence ~ Xtime). Next, the
effect of the intervention on glaucoma medication ad-
herence after adjustment for a mediator will be tested
(Ymedication adherence ~ Xtime + Xmediator). Lastly, the effect
of the intervention on a mediator will be tested (Ymedia-
tor ~ Xtime). After standardizing the effects from these
three models, the direct, indirect, and total effects of
the intervention will be estimated and Sobel’s test will
be used to test the significance of the indirect effect.
We will adjust for weekly and seasonal trends when
assessing other factors influencing adherence. We will use
time series analysis using the 2 years of daily adherence
data for each patient. Using Unobserved Component
Models (UCMs), weekly and seasonal (yearly) cycles will
be identified and tested in the context of a comprehensive
regression model that adjusts for covariates such as par-
ticipant characteristics and study intervention period.
After adjustment, we will test for trends, e.g., a gradual
improvement in adherence over time or a drop in adher-
ence post-intervention [84, 85]. The SAS procedures
TIMESERIES and UCM will be used for these analyses.
The UCM procedure handles missing values in the
dependent series and provides model diagnostics.
Secondary outcomes include comparing adherence
measured by pharmacy refill data, self-report, and suc-
cessful eye-drop instillation to electronic monitoring
using Pearson’s correlations. Changes in glaucoma skills
and energy for change will be assessed after each inter-
vention component and at 1 and 2 years
post-intervention and compared with paired t tests and
McNemar’s tests for continuous and categorical mea-
sures. All analyses will be conducted with SAS software,
version 9.4 (SAS Institute, Cary, NC, USA).
The semi-structured interviews will be recorded and
transcribed verbatim. Two investigators will read the
transcripts and identify major themes. The data will be
interpreted qualitatively using grounded theory [86]. A
code book will be generated defining codes for each
theme. Two investigators will then code the transcripts.
Any areas of disagreement will be discussed until con-
sensus is reached or adjudicated by a third researcher
[87]. The coded content will be tallied to weight the fre-
quency of the themes. The transcripts will also be ana-
lyzed by participant group, those who did and those who
did not improve from the intervention. Themes from
these two groups will be compared in a joint display to
try to identify reasons why the program was not success-
ful among some participants to identify areas for pro-
grammatic improvement.
Sample size
We estimate that 46 participants will provide 80% power to
detect at least a relative improvement of 15% in adherence
(from an average pre- to post-intervention adherence rate
of 0.7 to 0.8, and common standard deviation of 0.20) with
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a type-1 error rate of 5% and assuming a mild correlation
of 0.3 between pre- and post-intervention adherences. We
wanted adequate power to identify even a small effect size
to evaluate whether this novel clinic-based intervention has
any initial impact on adherence. This power calculation is
based on the study by Okeke et al. in which patients < 75%
adherent (measured with electronic monitors) were ran-
domized to a standard counseling intervention vs. regular
care [88]. This study demonstrated a 19% ± 20% improve-
ment in adherence in the intervention group. We will aim
to enroll 57 patients to allow for a 20% dropout rate; we
anticipate this dropout rate given that we are targeting
participants who are non-adherent to their recommended
medication treatments. We aim to enroll 15 African-
American patients to ensure that 25% of our patient popu-
lation is African-American.
Discussion
This project will develop and test technology-based,
individually-tailored, behavior change programs designed
to motivate people with glaucoma to improve their
medication adherence. It uses a pre-post design and be-
gins with automated reminders tailored to an individual’s
preference and escalates to a counseling intervention
aimed to help participants find their own solutions to
adherence barriers and increase their motivation to take
care of their glaucoma. The mixed methods design—
quantitative adherence data and qualitative patient inter-
view data—will enable us to test the intervention’s pre-
liminary efficacy as well as identify areas for future
improvement. The largest limitation to this pilot study is
inherent in its design: it lacks a control arm. In addition,
when participants know they are being monitored, they
may change their behavior. We will investigate our data
for this Hawthorne effect to estimate its impact on our
results. These data will serve to alllow us to assess the
feasibility of the intervention and test the plausibility of
the intervention's impact prior to evaluating it in a ran-
domized controlled clinical trial.
Creating a paradigm in which para-professional staff
can increase the reach of physicians by providing per-
sonalized education and counseling that is individualized
to the patient’s diagnosis, test results, treatment recom-
mendations, and barriers to optimal adherence will help
improve chronic disease self-management for glaucoma
patients. Research in this area is necessary to create a ro-
bust evidence-based model for dissemination of im-
proved best-practices for managing glaucoma. Strong
evidence that this type of personalized behavioral inter-
vention improves patient centered outcomes—such as
satisfaction with health care provider communication
and self-efficacy—alongside clinical outcomes—such as
medication adherence and intraocular pressure
fluctuation—will help inform policy decisions about re-
imbursing team-based care in the subspecialty setting in
a parallel way to the reimbursement structure used with
diabetic patients in primary care. Future work on inte-
grating glaucoma education into the clinical encounter
needs to be done to facilitate dissemination of any clinic-
ally useful results.
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